Caffeine based measures of CYP IA2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease

British Journal of Clinical Pharmacology

Volumn 46, Issue 3, 1998, Pages 221-228

  Fontana, Robert J ^a   DeVries, Tina M ^b   Woolf, Thomas F ^c   Knapp, Margaret J ^c   Brown, A S ^c   Kaminsky, Laurence S ^d   Tang, Bing Kuo ^e   Foster, Norman L ^f   Brown, Richard R ^c   Watkins, Paul B ^a,g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Rockaway 80 Corporate Center   (United States)

^c PFIZER INC   (United States)

^d WADSWORTH CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g Parke Davis   (United States)

Author keywords

Alzheimer's disease; Caffeine; Cytochrome P450; Metabolism; Pharmacokinetics; Tacrine

Indexed keywords

CAFFEINE; CYTOCHROME P450; PARAXANTHINE; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAFFEINE; CHOLINESTERASE INHIBITORS; CYTOCHROME P-450 CYP1A2; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PREDICTIVE VALUE OF TESTS; TACRINE;

EID: 7344220960     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00776.x     Document Type: Article

References (48)

1. Farlow M. Management of Alzheimer's Disease: Today's Options and Tomorrow's Opportunities. Alz Dis Assoc Disord 1994; 8(Suppl 2): S50-S57.
2. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
3. Parke-Davis Pharmaceuticals Warner Lambert. Cognex (tacrine) package insert. Parke Davis Pharm 1994.
4. Ford JM, Truman CA, Wilcock GK, Roberts CJ. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993; 53: 691-695.
5. Hartvig P, Askmark H, Aquilonius SM, Wiklund L, Lindstrom B. Clinical Pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, Tacrine. Eur Clin Pharmacol 1990; 38: 259-263.
6. Ahlin A, Adem A, Junthe T, Ohman G, Nyback H. Pharmacokinetics of tetrahydroamino-acridine: relations to clinical and biochemical effects in Alzheimer patients. Int Clin Psychopharmacol 1992; 7: 29-36.
7. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-7700.
8. Madden, S., Woolf TF, Pool WF, Park K. An investigation into formation of stable,protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem Pharmacol 1993; 46: 13-20.
9. Woolf TF, Pool WF, Bjorge S, Chang T, Goel OP, Trager WF. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal prepcrations. Drug Metab Dispos 1993; 21: 1-9.
10. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363-372.
11. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
12. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23: 1429-1435.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. Neurology 1984; 34: 939-944.
14. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170-180.
15. Nousbaum JB, Berthou F, Carlhant D, Gouerou H, Riche C, Robaszkiewiez M. Four-week treatment with omeprazole increases the metabolism of caffeine. Am J Gastro 1994; 89: 371-375.
16. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterization of human liver cytochromes P450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20: 31-37.
17. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 1991; 101: 1680-1692.
18. Sinha R, Rothman N, Brown ED, et al. Pan-fried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501a2 activity in humans. Cancer Res 1994; 54: 6154-6159.
19. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1995; 55: 431-436.
20. Juan D, Worwag EM, Schoeller DA, Kotake AN, Hughes RL, Frederiksen MC. Effects of dietary-protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. Clin Pharmacol Ther 1986; 40: 187-194.
21. Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD, Josephs H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32: 261-269.
22. Wietholtz H, Voegelin M, Arnaud MJ, Bircher J, Preisig R. Assessment of the cytochrome P-448 Dependent liver enzyme System by a caffeine breath test. Eur J Clin Pharmacol 1981; 21: 53-59.
23. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
24. Zhang Z, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995; 50: 205-211.
25. Tang B-K, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4: 117-124.
26. Haughey DB, McNaney CA, Collis MS, et al. Simultaneous determination of tacrine, 1-hydroxy-,2-hydroxy-, 4-hydroxytacrine in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1994; 573: 93-95.
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
28. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-165.
29. Kalow W, Tang BK. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49: 44-48.
30. Denaro CP, Benowitz NL. Caffeine metabolism: disposition in liver disease and hepatic-function testing. In Drug and alcohol abuse reviews, vol. 2: liver pathology and alcohol, 513-539. eds Watson RR, Clifton NJ, The Humana Press, 1991.
31. Cutler NR, Sedman AJ, Prior P, Underwood BA, Selen A, Gracon SI. Steady state pharmacokinetics of tacrine in patients with Alzheimer's disease. Psychopharmacology Bulletin 1990; 26: 231-234.
32. Forsyth DR, Morgan R, Truman CA, Ford JM, Wilcock GK, Roberts CJC. Pharmacokinetics of tacrine hydrochloride in patients with dementia. Proceedings of the BPS 1988; 19-21: 674-675.
33. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJ. Pharmacokinetics of tacrine hydrochloride in Alzheimers disease. Clin Pharmacol Ther 1989; 46: 634-641.
34. Wagstaff AJ, McTavish D. Tacrine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's Disease. Drugs and Aging 1996; 4: 510-540.
35. Truman CA, Ford JM, Roberts CJC. Comparison of the chromatographic characteristics of metabolites of tacrine hydrochloride in human serum and urine with those of in vitro metabolic products from hepatic microsomes. Biochem Pharmacol 1991; 42: 956-959.
36. Relling MV, Lin J, Ayers GD, Evans WE. Racial and gender differences in N-acetyl tranferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643-658.
37. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
38. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-159.
39. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: Potential implication for the hepatotoxicity in vivo. Fundam Clin Pharm 1996; 10: 156-157.
40. Forgue ST, Reece PA, Sedman AJ, deVries TM. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1996; 59: 444-449.
41. Becquemont L. Ragueneau I, Le Bot A, Riche C, Brentano CF, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619-627.
42. Fuhr U, Rost KL, Engelhardt R, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6: 159-176.
43. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149.
44. Renner E, Wietholtz H, Huguenin P, Amaud MJ, Preisig R. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4: 38-46.
45. Pons G, Blais JC, Rev E. Maturation of caffeine N-demethylation in infancy: A study using the [13]CO2 breath test. Pediatr Res 1988; 23: 632-636.
46. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-411.
47. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK. (1995) Determination of human hepatic cytochrome P4501A2 activity in vitro-Use of tacrine as an isoenzyme-specific probe. In Drug Metabolism and Disposition: The Biological Fate of Chemicals, 1995; 929-934.
48. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolic activation of tacrine by human liver enzymes. Br J Clin Pharmacol 1994; 38: 15-22.